Afshar Oromieh A, Debus N, Uhrig M, Hope TA, Evans MJ, Holland-Letz T, Giesel FL, Kopka K, Hadaschik B, Kratochwil C, Haberkorn U (2018). Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer. EUR J NUCL MED MOL I, 45(12): 2045-54.

Afshar Oromieh A, Sattler LP, Steiger K, Holland-Letz T, da Cunha ML, Mier W, Neels O, Kopka K, Weichert W, Haberkorn U (2018). Tracer uptake in mediastinal and paraaortal thoracic lymph nodes as a potential pitfall in image interpretation of PSMA ligand PET/CT. EUR J NUCL MED MOL I, 45(7): 1179-87.

Brendel M, Jaworska A, Overhoff F, Blume T, Probst F, Gildehaus FJ, Bartenstein P, Haass C, Bohrmann B, Herms J, Willem M, Rominger A (2018). Efficacy of chronic BACE1 inhibition in PS2APP mice depends on the regional Aβ deposition rate and plaque burden at treatment initiation. THERANOSTICS, 8(18): 4957-68.

Brendel M, Sauerbeck J, Greven S, Kotz S, Scheiwein F, Blautzik J, Delker A, Pogarell O, Ishii K, Bartenstein P, Rominger A (2018). Serotonin Selective Reuptake Inhibitor Treatment Improves Cognition and Grey Matter Atrophy but not Amyloid Burden During Two-Year Follow-Up in Mild Cognitive Impairment and Alzheimer’s Disease Patients with Depressive Symptoms. J ALZHEIMERS DIS, 65(3): 793-806.

Läppchen T, Holland JP, Kiefer Y, Bartholomä MD (2018). Preparation and preclinical evaluation of a 68Ga-labelled c(RGDfK) conjugate comprising the bifunctional chelator NODIA-Me. EJNMMI radiopharm. chem., 3(1): 6.

Läppchen T, Kiefer Y, Holland JP, Bartholomä MD (2018). In vitro and in vivo evaluation of the bifunctional chelator NODIA-Me in combination with a prostate-specific membrane antigen targeting vector. NUCL MED BIOL, 60: 45-54.

Balmelli C, Railic N, Siano M, Feuerlein K, Cathomas R, Cristina V, Güthner C, Zimmermann S, Weidner SE, Pless M, Stenner F, Rothschild SI (2018). Lenvatinib in Advanced Radioiodine-Refractory Thyroid Cancer - A Retrospective Analysis of the Swiss Lenvatinib Named Patient Program. J CANCER, 9(2): 250-5.

Beyer L, Meyer-Wilmes J, Schönecker S, Schnabel J, Brendel E, Prix C, Nübling G, Unterrainer M, Albert NL, Pogarell O, Perneczky R, Catak C, Bürger K, Bartenstein P, Bötzel K, Levin J, Rominger A, Brendel M (2018). Clinical Routine FDG-PET Imaging of Suspected Progressive Supranuclear Palsy and Corticobasal Degeneration: A Gatekeeper for Subsequent Tau-PET Imaging? FRONT NEUROL, 9(483): 483.

Blume T, Focke C, Peters F, Deussing M, Albert NL, Lindner S, Gildehaus FJ, von Ungern-Sternberg B, Ozmen L, Baumann K, Bartenstein P, Rominger A, Herms J, Brendel M (2018). Microglial response to increasing amyloid load saturates with aging: a longitudinal dual tracer in vivo μPET-study. J NEUROINFLAMM, 15(1): 307.

Debus C, Afshar Oromieh A, Floca R, Ingrisch M, Knoll M, Debus J, Haberkorn U, Abdollahi A (2018). Feasibility and robustness of dynamic 18F-FET PET based tracer kinetic models applied to patients with recurrent high-grade glioma prior to carbon ion irradiation. SCI REP-UK, 8(1): 14760.

Guo T, Dukart J, Brendel M, Rominger A, Grimmer T, Yakushev I (2018). Rate of β-amyloid accumulation varies with baseline amyloid burden: Implications for anti-amyloid drug trials. Alzheimer's and dementia, 14(11): 1387-96.

Kaida H, Azuma K, Kawahara A, Sadashima E, Hattori S, Takamori S, Akiba J, Fujimoto K, Rominger A, Murakami T, Ishii K, Ishibashi M (2018). The assessment of correlation and prognosis among ¹⁸F-FDG uptake parameters, Glut1, pStat1 and pStat3 in surgically resected non-small cell lung cancer patients. ONCOTARGET, 9(62): 31971-84.

Mix M, Reichel K, Stoykow C, Bartholomä M, Drendel V, Gourni E, Wetterauer U, Schultze-Seemann W, Meyer PT, Jilg CA (2018). Performance of 111In-labelled PSMA ligand in patients with nodal metastatic prostate cancer: correlation between tracer uptake and histopathology from lymphadenectomy. EUR J NUCL MED MOL I, 45(12): 2062-70.

Rahbar K, Afshar Oromieh A, Bögemann M, Wagner S, Schäfers M, Stegger L, Weckesser M (2018). F-PSMA-1007 PET/CT at 60 and 120 minutes in patients with prostate cancer: biodistribution, tumour detection and activity kinetics. EUR J NUCL MED MOL I, 45(8): 1329-34.

Rahbar K, Afshar Oromieh A, Seifert R, Wagner S, Schäfers M, Bögemann M, Weckesser M (2018). Diagnostic performance of 18F-PSMA-1007 PET/CT in patients with biochemical recurrent prostate cancer. EUR J NUCL MED MOL I, 45(12): 2055-61.

Voltin CA, Goergen H, Baues C, Fuchs M, Mettler J, Kreissl S, Oertl J, Klaeser B, Moccia A, Drzezga A, Engert A, Borchmann P, Dietlein M, Kobe C (2018). Value of bone marrow biopsy in Hodgkin lymphoma patients staged by FDG PET: results from the German Hodgkin Study Group trials HD16, HD17, and HD18. ANN ONCOL, 29(9): 1926-31.

Weinmann C, Holland JP, Läppchen T, Scherer H, Maus S, Stemler T, Bohnenberger H, Ezziddin S, Kurz P, Bartholomä MD (2018). Optimized synthesis and indium complex formation with the bifunctional chelator NODIA-Me. ORG BIOMOL CHEM, 16(40): 7503-12.

Zacho HD, Nielsen JB, Afshar Oromieh A, Haberkorn U, deSouza N, De Paepe K, Dettmann K, Langkilde NC, Haarmark C, Fisker RV, Arp DT, Carl J, Jensen JB, Petersen LJ (2018). Prospective comparison of 68Ga-PSMA PET/CT, 18F-sodium fluoride PET/CT and diffusion weighted-MRI at for the detection of bone metastases in biochemically recurrent prostate cancer. EUR J NUCL MED MOL I, 45(11): 1884-97.

Beyer L, Rominger AO (2018). Neuro-PET – ein Update. Der Nuklearmediziner, 41(03): 253-63.

Wiest R, Rominger AO (2018). Bildgebung bei Epilepsie: Neue Ansätze in Forschung und Praxis. INFO, 16(5): 4-10.

Afshar Oromieh A (2018) Tracer uptake in mediastinal lymph nodes as a potential pitfall in image interpretation of PSMA Ligand PET/CT. In: DGN-Kongresse, 30. Oktober – 3. November 2018.

Beyer L, Meyer-Wilmes J, Schönecker S, Schnabel J, Brendel E, Unterrainer M, Catak C, Pogarell O, Perneczky R, Danek A, Bürger K, Bartenstein P, Levin J, Rominger A, Brendel M (2018). Left Temporal Hypometabolism in FDG-PET underlines Cognitive Reserve Hypothesis in Frontotemporal Dementia. EUR J NUCL MED MOL I, 45(S1): S408.

Beyer L, Schnabel J, Kazmierczak P, Schönecker S, Prix C, Meyer-Wilmes J, Unterrainer M, Catak C, Pogarell O, Perneczky R, Ewers M, Bartenstein P, Danek A, Bürger K, Levin J, Rominger A, Brendel M (2018). Neuronal Injury Biomarkers for Assessment of Cognitive Reserve in Alzheimer’s Disease. EUR J NUCL MED MOL I, 45(S1): S228-9.

Boy C, Poeppel T, Kotzerke J, Krause BJ, Amthauer H, Baum RP, Buchmann I, Ezziddin S, Führer D, Gabriel M, Kuwert T, Lahner H, Lauenstein T, Maecke HR, Nagarajah J, Rösch F, Scheidhauer K, Schmidt M, Walter MA, Bockisch A (2018). Somatostatinrezeptor-PET/CT. NUKLEARMED-NUCL MED, 57(01): 4-17.

Brendel M, Focke C, Deussing M, Zott B, Blune T, Shi Y, Beyer L, Kleinberger G, Lindner S, Gildehaus F, Bartenstein P, Baumann K, Haass C, Herms J, Adelsberger H, Rominger A (2018). Early and longitudinal microglial activation but not fibrillar amyloid accumulation predict cognitive outcome and synaptic density in PS2APP mice. EUR J NUCL MED MOL I, 45(S1): S206-7.

Dijkstra L, Haupt F, Viscione M, Fech V, Krause TM, Rominger AO, Afshar Oromieh A (2018) Standard protocol compared to a novel protocol for 68Ga-PSMA-PET/CT in patients with recurrent prostate cancer - which one is superior? EUR J NUCL MED MOL I, 45(S1): S163.

Haupt F (2018). Expert System for Bone Scan Interpretation Improves Progression Assessment in Bone Metastatic Prostate Cancer (Dissertation).

Hope TA, Afshar Oromieh A, Eiber M, Emmett L, Fendler WP, Lawhn-Heath C, Rowe SP (2018). Imaging Prostate Cancer With Prostate-Specific Membrane Antigen PET/CT and PET/MRI: Current and Future Applications. AM J ROENTGENOL, 211(2): 286-94.

Klaeser B, Prenosil G, Hentschel M, Fürstner M, Krause TM, Rominger A, Weitzel T (2018). Results of a nationwide phantom based PET-Survey in Switzerland before harmonization. EUR J NUCL MED MOL I, 45(S1): S59.

Li WB, Zhernosekov K, Höllriegl V, Meckel M, Ziegler S, Konijnenberg MW, Shi K (2018). Feasibility study of applying ICRP biokinetic models for pharmacokinetic modelling of alpha-emitter thorium-227 used in targeted radionuclide therapy. EUR J NUCL MED MOL I, 45(S1): S125.

Murray JR, Kopka K, Afshar-Oromieh A (2018). Imaging and radiotherapy for recurrent prostate cancer: An evolutionary partnership. RADIOTHER ONCOL, 129(2): 387-8.

Poeppel TD, Handkiewicz-Junak D, Andreeff M, Becherer A, Bockisch A, Fricke E, Geworski L, Heinzel A, Krause BJ, Krause T, Mitterhauser M, Sonnenschein W, Bodei L, Delgado-Bolton RC, Gabriel M (2018). EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer. EUR J NUCL MED MOL I, 45(5): 824-45.

Prenosil G, Weitzel T, Hentschel M, Krause TM, Rominger A, Klaeser B (2018). Quantitative PET: Count Number Adaptations of Organ and Site specific Acquisition Protocols are a Key Determinant of comparable PET/CT Measurements. EUR J NUCL MED MOL I, 45(S1): S311-2.

Rahbar K, Afshar Oromieh A, Jadvar H, Ahmadzadehfar H (2018). PSMA Theranostics: Current Status and Future Directions. MOL IMAGING, 17: 1536012118776068.

Sauerbeck J, Beyer L, Rohrer G, Sonnenfeld S, Nübling G, Höglinger G, Bartenstein P, Levin J, Rominger A, Brendel M (2018). In vivo Imaging of Microglial Activation in Patients with Clinical Suspected Progressive Supranuclear Palsy: A 18FGE180 PET study. EUR J NUCL MED MOL I, 45(S1): S267.

Shi K, Grimmer T, Förstl H, Yakushev I, Schwaiger M, Weber W, Kurz A, Yousefi BH (2018). Amyloid Imaging using 18F-FIBT PET: a pilot study. EUR J NUCL MED MOL I, 45(S1): S133.

Shi K, Xu L, Tetteh G, Gafita A, Haupt F, Afshar Oromieh A, Eiber M, Menze BH, Rominger A (2018). Multi-Task Deep Learning for the Detection of Lesions on 68Ga-PSMA PET/CT Imaging. EUR J NUCL MED MOL I, 45(S1): S43.

Tetteh G, Gafita A, Xu L, Zhao Y, Dong C, Rominger A, Shi K, Zimmer C, Menze BH, Eiber M (2018). Fully Convolutional Neural Network to Assess Skeleton Tumor Burden in Prostate Cancer Using 68Ga-PSMA-11 PET/CT: Preliminary Results. EUR J NUCL MED MOL I, 45(S1): S41.

Weitzel T, Prenosil G, Hentschel M, Fürstner M, Krause TM, Rominger A, Klaeser B (2018). Evaluation of Multi-Center PET/CT Quality Assurance: Multi-Paradigm Software Enables Automated PET Quality Control. EUR J NUCL MED MOL I, 45(S1): S310-1.